Skip to main content
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Clinical Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • Clinical Compendia
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Clinical Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • Clinical Compendia
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
Departments

Effects of the Medicare Modernization Act on Clinicians Involved in Diabetes Care

  1. Steven B. Leichter, MD, FACP, FACE
    Clinical Diabetes 2006 Jan; 24(1): 12-13. https://doi.org/10.2337/diaclin.24.1.12
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Within the next few months, the federal government will implement the first major reorganization of the Medicare system for many years: the Medicare Prescription Drug Improvement and Modernization Act of 20031 (Table 1). The plan called “Medicare Part D” offers two major changes to the current system. First, it offers a pharmacy benefit to eligible seniors. An extensive discussion of this part of the Act may be found in a recent edition of the online Wall Street Journal.2 The second and indirect effect of this reform may be to encourage the organization of Medicare recipients into managed care plans, which would function like other managed care plans.3 For seniors and other Medicare recipients who have diabetes, both aspects will substantially affect their health care. Those of us who render diabetes care to Medicare recipients should prospectively consider how these changes will affect our processes of care and plan accordingly.

    View this table:
    • View inline
    • View popup
    • Download powerpoint
    Table 1.

    Primary Effects of Medicare Part D

    Medicare Part D: Pharmacy Benefit Plans

    As Medicare Part D is implemented, eligible participants will be offered a variety of plans to cover the costs of prescription drugs. In many localities, the options may be varied and confusing.4 They may range from plans with low monthly premiums that provide partial or complete coverage for generic drugs only to plans with much higher premiums that will offer choices and include brand-name products.

    No matter which plan patients select, there will be three overall effects of the advent of these programs. The first is that plans with the largest roster of enrollees will have the largest negotiating clout with pharmaceutical companies when deciding which drugs will be included in specific plans. The second is that generic drugs will constitute the backbone of all of these plans. The third is that large managed care or insurance companies will get access to substantial segments of the Medicare population to sell Medicare-related health insurance products or supplements as well as pharmacy benefit plans. Each of these effects will probably exert important influences in reshaping the pattern of health care for senior citizens in the United States.

    There is a growing weight of opinion that the advent of Medicare Part D will alter the relative position of pharmaceutical companies and pharmacy benefits providers and insurance companies that plan to offer Medicare Part D services.5 The emphasis on generic or low-cost drugs will possibly put substantial pressure on large pharmaceutical companies to alter the pricing on their premium drugs or face exclusion from pharmacy plans. Analysts suggest that companies such as Pfizer, which depend on brand-name drugs such as atorvastatin for much of their profits, may face growing market worries about the position of those drugs, if, as in the case of atorvastatin, there are credible alternatives available.

    Generic drug manufacturers, pharmaceutical companies willing to negotiate discounts on their products, and companies with unique drugs may fare better in the coming market environment. Indeed, analysts cite issues between Pfizer and Express Scripts regarding the inclusion of atorvastatin and other Pfizer products in the formularies offered to Express Scripts customers6 as examples of evolving changes in the dynamics of this marketplace.

    A constant theme in most predictions is that the importance of generic drugs will increase. Most, if not all, Medicare Part D plans will strongly encourage participants to use generic products. This will be accomplished by limiting most lower-cost Part D pharmacy plans to coverage of generic drugs only or by requiring significant differences in participant copayments for brand-name versus generic agents.5 There is some suggestion that the structure of many of these plans will discourage participants from selecting more expensive products. The array of plans has been confusing to many seniors,7 and there is appropriate skepticism among them about whether these programs will actually save them money.8 There is some worry about opportunities for fraud in this market, as well.9

    Implications for Medicare Beneficiaries and Providers

    The provision of services through large health care insurance or benefits companies will strengthen their presence in the Medicare marketplace. Enrollees in pharmacy plans will be targets for health insurance products of those pharmacy plan companies or of companies with which the pharmacy plans become affiliated.10 A growing percent of the Medicare population will become enrolled in managed care plans.

    At the same time, Medicare has authorized a series of initiatives to assess the clinical outcomes of treatment of beneficiaries in specific disease-state areas, including diabetes.11 This will present insurers with enhanced opportunity for disease-state management programs to reduce the costs of services to these participants and to impose stricter standards of care on the providers who serve these populations.12 These sorts of contracts are being specifically advocated for diabetic Medicare recipients.13

    These changes may profoundly affect the process of care for diabetic Medicare recipients. The possible impacts of specific changes are worrisome for both patients and providers. Patient advocates, provider organizations, and national advocacy groups such as the American Diabetes Association should observe these changes with concern and care.

    In a previous commentary,14 I raised concerns over whether changes in the terms of service for Medicare patients were making that group an unattractive population to providers. As more and more of these patients become enrolled in managed care organizations, they will become subject to the growing trend to monitor the outcomes of care. Performance indicators, such as hemoglobin A1c will be used to measure outcomes.13 As more pressure is placed on providers to achieve clinical goals, they will likely prefer the most effective drugs for treatment. These may be the most expensive treatments, which may not be covered by their patients' pharmacy plans. Providers will then have to devote significantly increased time and effort to obtaining approvals from the managed care formularies for those drugs. Such pressure may cause providers to exclude Medicare recipients from their patient base. In the end, these pressures are just as likely to harm diabetic Medicare patients as these plans are to help them.

    Therefore, the rush to more highly organize the care of Medicare patients should be considered with some eye toward the pressures this effort may generate on the provider base that serves this population. One possible outcome would be highly undesirable: that managed care plans require providers to achieve positive clinical goals in diabetic patients with the least expensive formulary possible. In that scenario, a disproportionate amount of clinical and financial risk will be transferred from insurers to providers. It is just this type of pressure that could encourage providers to avoid treating diabetic Medicare recipients.

    Footnotes

    • Steven B. Leichter, MD, FACP, FACE, is co-director of the Columbus Research Foundation and president of Endocrine Consultants, PC, in Columbus, Ga. He is a professor of medicine at Mercer University School of Medicine in Macon, Ga.

    • American Diabetes Association

    References

    1. ↵
      Centers for Medicare and Medicaid Services: Medicare Modernization Act 2005 [article online]. U.S. Department of Health and Human Services. Available from http://www.cms.hhs.gov/medicarereform/
    2. ↵
      Medicare drug benefit [article online]. Wall Street Journal Online 12 October 2005. Available from http://online.wsj.com/page/2_1185.html?mod=home_in_depth_reports
    3. ↵
      Gold M: Private plans in Medicare: another look. Health Aff24 : 1302-1310,2005
      OpenUrlAbstract/FREE Full Text
    4. ↵
      Martinez B, Lueck S: How to choose a Medicare drug plan. Wall Street Journal Online 4 October 2005. Available from http://online.wsj.com/article/SB112838549388659079.html?mod=2_1185_1
    5. ↵
      Davies P: Medicare drug plan: which big pharma wins? Wall Street Journal Online 11 October 2005. Available from http://online.wsj.com/article/SB112898416023064873.html?mod=2_1185_1
    6. ↵
      Alpert B: Pfizer's new headache. Barrons Online. October 2005. Available from http://online.barrons.com/article/SB112872627432763274-search.html
    7. ↵
      Rubenstein S: Seniors consider costs of Medicare drug plans. Wall Street Journal Online 21 October 2005. Available from http://online.wsj.com/article/SB112913603385066806.html?mod=2_1185_2
    8. ↵
      Havdra DE, Omundsen BA, Bender W, Kirkpatrick MA: Impact of Medicare Modernization Act on low-income persons. Arch Intern Med143 : 600-608,2005
      OpenUrl
    9. ↵
      Greene K: Avoid drug-plan scams. Wall Street Journal Online October 16, 2005. Available from http://online.wsj.com/article/SB112941555339869867.html?mod=2_1185_1
    10. ↵
      Medicare: Decisions, decisions. Business Week Online 5 October 2005. Available from http://www.businessweek.com/@@wRHT34UQZbAW0RoA/magazine/content/05_40/b3953124.htm
    11. ↵
      Haffner SC, Bowen S: Medicare Health Outcomes Survey Evaluation [article online]. Baltimore, Md., Delmarva Foundation, 27 December 2004. Available from http://www.cms.hhs.gov/surveys/hos/download/HOS_Evaluation_Final_Report.pdf#search=`Medicare%20D%20AND%20outcomes'
    12. ↵
      The manager: using performance-based payments to improve health programs. Management Strategies to Improve Health Services. vol. 10, 2001. Available from http://www.msh.org/what_MSH_does/hiv/pdf/performance_based.pdf#search=`Performance%20based%20health%20insurance%20contracts'
    13. ↵
      Fleming BB, Greenfield S, Engelglau MM, Pogach LM, Clauser SB, Parrott MA: The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic. Diabetes Care24 : 1815-1820,2001
      OpenUrlFREE Full Text
    14. ↵
      Leichter SB: Third party reimbursement: now comes the really hard part. Clin Diabetes 21:175 -178, 2003
      OpenUrlFREE Full Text
    PreviousNext
    Back to top

    In this Issue

    January 2006, 24(1)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Clinical Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Effects of the Medicare Modernization Act on Clinicians Involved in Diabetes Care
    (Your Name) has forwarded a page to you from Clinical Diabetes
    (Your Name) thought you would like to see this page from the Clinical Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Effects of the Medicare Modernization Act on Clinicians Involved in Diabetes Care
    Steven B. Leichter
    Clinical Diabetes Jan 2006, 24 (1) 12-13; DOI: 10.2337/diaclin.24.1.12

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Effects of the Medicare Modernization Act on Clinicians Involved in Diabetes Care
    Steven B. Leichter
    Clinical Diabetes Jan 2006, 24 (1) 12-13; DOI: 10.2337/diaclin.24.1.12
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Medicare Part D: Pharmacy Benefit Plans
      • Implications for Medicare Beneficiaries and Providers
      • Footnotes
      • References
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients
    • Gvoke HypoPen: An Auto-Injector Containing an Innovative, Liquid-Stable Glucagon Formulation for Use in Severe Acute Hypoglycemia
    • Timely News and Notes for Primary Care Providers from the American Diabetes Association
    Show more Departments

    Similar Articles

    Navigate

    • Current Issue
    • Papers in Press
    • Abridged Standards of Care
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Clinical Diabetes Print ISSN: 0891-8929, Online ISSN: 1945-4953.